Skip to main content
Ensol Biosciences Inc. logo

Ensol Biosciences Inc. — Investor Relations & Filings

Ticker · 140610 ISIN · KR7140610007 KO Manufacturing
Open in API
Filings indexed 257 across all filing types
Latest filing 2024-03-20 Regulatory Filings
Country KR South Korea
Listing KO 140610

About Ensol Biosciences Inc.

https://www.ensolbio.co.kr/eng/

Ensol Biosciences Inc. is a biopharmaceutical company focused on developing innovative drugs for diseases with limited or no therapeutic alternatives. The company leverages a bio big data and AI-driven platform for its research and development activities. A core area of its technology involves Protein-Protein Interaction (PPI)-regulating short peptide drugs, which are designed for local injection to maximize therapeutic effects and minimize systemic side effects through high specificity and a short half-life in the blood. The company's pipeline targets a range of medical unmet needs, including degenerative disc disease, osteoarthritis, cancer, and neurodegenerative disorders like Alzheimer's disease. Key clinical-stage assets include E1K for osteoarthritis (preparing for Phase 3) and C1K, an anticancer combination therapy (Phase 1).

Recent filings

Filing Released Lang Actions
기타주요경영사항(자율공시) (감사보고서 제출 지연)
Regulatory Filings Classification · 100% confidence The document is a regulatory announcement from Ensol Biosciences regarding the delay in submitting their audit report. It is a short, formal notification (under 5,000 characters) explaining that the audit process is not yet complete and the report will be filed later. Since it does not contain the actual audit report but rather announces a delay in its publication, it falls under the category of a regulatory filing or announcement.
2024-03-20 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집 결의) for Ensol Biosciences. It outlines the date, location, and specific agenda items (financial statement approval, director appointments, remuneration limits, and stock option grants). This type of document is a standard proxy solicitation/information statement provided to shareholders to inform them of upcoming meeting details and voting items.
2024-03-13 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Ensol Biosciences. It contains the agenda for the upcoming Annual General Meeting (AGM), including items such as the approval of financial statements, election of directors, and remuneration limits. While it contains financial data (balance sheets, income statements) as part of the 'management reference materials' required for shareholder review, the primary purpose of the document is to formally convene the shareholders for the meeting. Therefore, it is classified as AGM-related materials.
2024-03-13 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required under the Capital Markets Act in South Korea when an entity's shareholding in a company crosses certain thresholds (typically 5%). This document details the shareholding changes of 'Tiger Asset Management' in 'Ensol Biosciences'. This falls under the 'Major Shareholding Notification' category.
2024-03-08 Korean
전환사채(해외전환사채포함)발행후만기전사채취득 (제1회차)
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from Ensol Biosciences regarding the early redemption (repurchase) of convertible bonds (1st series) due to a put option exercised by the bondholder. This falls under capital structure changes and financing updates, specifically related to debt instruments. Given the specific nature of the filing regarding the acquisition of its own debt securities, it fits best under the 'CAP' (Capital/Financing Update) category.
2024-02-16 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the changes in share ownership by Tiger Asset Management in Ensol Biosciences. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant ownership thresholds and changes.
2024-01-10 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.